Funding for this research was provided by:
National Institutes of Health (NIDDK (1K23DK117055-01A1))
Article History
Received: 23 September 2020
Accepted: 6 December 2020
First Online: 2 January 2021
Compliance with Ethical Standards
:
: Neehar Parikh serves as a consultant for Bristol Myers-Squibb, Exact Sciences, Eli Lilly, Freenome, has served on advisory boards of Genentech, Easai, Bayer, Exelexis, Wako/Fujifilm, and has received research funding from Bayer, Target Pharmasolutions, Exact Sciences, and Glycotest. Elliot Tapper has served as a consultant to Novartis, Kaleido, Axcella, and Allergan, has served on advisory boards for Mallinckrodt, Rebiotix, and Bausch Health, and has received unrestricted research grants from Gilead and Valeant. The remaining authors indicate no potential conflicts of interest.